Pitcairn’s DexCom DXCM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-10,399
| Closed | -$700K | – | 165 |
|
|
2025
Q3 | $700K | Sell |
10,399
-7,539
| -42% | -$597K | 0.06% | 277 |
|
|
2025
Q2 | $1.57M | Sell |
17,938
-3,414
| -16% | -$268K | 0.1% | 186 |
|
|
2025
Q1 | $1.46M | Sell |
21,352
-46
| -0.2% | -$3.75K | 0.09% | 203 |
|
|
2024
Q4 | $1.66M | Sell |
21,398
-215
| -1% | -$15.9K | 0.1% | 184 |
|
|
2024
Q3 | $1.45M | Sell |
21,613
-13,769
| -39% | -$1.13M | 0.09% | 211 |
|
|
2024
Q2 | $4.01M | Buy |
35,382
+2,586
| +8% | +$327K | 0.25% | 73 |
|
|
2024
Q1 | $4.55M | Sell |
32,796
-4,796
| -13% | -$603K | 0.29% | 58 |
|
|
2023
Q4 | $4.66M | Sell |
37,592
-16,491
| -30% | -$1.68M | 0.34% | 47 |
|
|
2023
Q3 | $5.05M | Buy |
54,083
+8,470
| +19% | +$955K | 0.42% | 39 |
|
|
2023
Q2 | $5.86M | Sell |
45,613
-934
| -2% | -$113K | 0.49% | 32 |
|
|
2023
Q1 | $5.41M | Sell |
46,547
-2,216
| -5% | -$248K | 0.5% | 31 |
|
|
2022
Q4 | $5.52M | Buy |
48,763
+120
| +0.2% | +$13.2K | 0.55% | 31 |
|
|
2022
Q3 | $3.92M | Sell |
48,643
-398
| -0.8% | -$33.7K | 0.42% | 34 |
|
|
2022
Q2 | $3.65M | Sell |
49,041
-2,411
| -5% | -$220K | 0.39% | 41 |
|
|
2022
Q1 | $6.58M | Buy |
51,452
+1,404
| +3% | +$154K | 0.57% | 24 |
|
|
2021
Q4 | $6.72M | Hold |
50,048
| – | – | 0.43% | 30 |
|
|
2021
Q3 | $6.84M | Sell |
50,048
-3,032
| -6% | -$382K | 0.47% | 27 |
|
|
2021
Q2 | $5.67M | Sell |
53,080
-4
| -0% | -$384 | 0.38% | 33 |
|
|
2021
Q1 | $4.77M | Buy |
53,084
+872
| +2% | +$81.9K | 0.34% | 40 |
|
|
2020
Q4 | $4.83M | Sell |
52,212
-400
| -0.8% | -$35.7K | 0.37% | 39 |
|
|
2020
Q3 | $5.42M | Sell |
52,612
-1,192
| -2% | -$125K | 0.46% | 32 |
|
|
2020
Q2 | $5.45M | Sell |
53,804
-10,284
| -16% | -$920K | 0.52% | 27 |
|
|
2020
Q1 | $4.31M | Sell |
64,088
-23,052
| -26% | -$1.43M | 0.51% | 24 |
|
|
2019
Q4 | $4.76M | Buy |
87,140
+176
| +0.2% | +$8.35K | 0.44% | 30 |
|
|
2019
Q3 | $3.24M | Sell |
86,964
-2,880
| -3% | -$112K | 0.32% | 45 |
|
|
2019
Q2 | $3.37M | Sell |
89,844
-1,832
| -2% | -$57.6K | 0.34% | 43 |
|
|
2019
Q1 | $2.73M | Sell |
91,676
-1,916
| -2% | -$67.3K | 0.3% | 46 |
|
|
2018
Q4 | $2.8M | Sell |
93,592
-2,632
| -3% | -$83.5K | 0.31% | 46 |
|
|
2018
Q3 | $3.44M | Sell |
96,224
-1,632
| -2% | -$50.6K | 0.36% | 38 |
|
|
2018
Q2 | $2.32M | Sell |
97,856
-3,036
| -3% | -$64.4K | 0.25% | 51 |
|
|
2018
Q1 | $1.87M | Sell |
100,892
-18,296
| -15% | -$271K | 0.2% | 60 |
|
|
2017
Q4 | $1.71M | Sell |
119,188
-644
| -0.5% | -$8.37K | 0.17% | 75 |
|
|
2017
Q3 | $1.47M | Buy |
119,832
+57,040
| +91% | +$1.01M | 0.17% | 86 |
|
|
2017
Q2 | $1.15M | Sell |
62,792
-640
| -1% | -$11.8K | 0.14% | 103 |
|
|
2017
Q1 | $1.34M | Sell |
63,432
-65,648
| -51% | -$1.28M | 0.16% | 92 |
|
|
2016
Q4 | $1.93M | Buy |
129,080
+37,736
| +41% | +$669K | 0.24% | 64 |
|
|
2016
Q3 | $2M | Buy |
+91,344
| New | +$2.03M | 0.25% | 56 |
|
Other funds holding DXCM
JSC
Pitcairn's DXCM Position: Q4 2025 in Review
Pitcairn sold out of DexCom (DXCM) in Q4 2025, closing a stake of 10,399 shares — an estimated $700K sold.
Pitcairn first reported a position in DXCM in Q3 2016 and held it in 37 quarters. The position peaked at $6.84M in Q3 2021. 920 funds tracked by Wall St. Rank hold DXCM as of Q4 2025.
- Pitcairn reported no remaining DexCom position as of Q4 2025 after selling out during the quarter.
- Pitcairn sold 10,399 DexCom shares in Q4 2025, an estimated $700K.
- Pitcairn first reported a position in DexCom in Q3 2016 and held it in 37 quarters.
- Pitcairn's DexCom position peaked at $6.84M in Q3 2021.
- 920 funds tracked by Wall St. Rank held DexCom as of Q4 2025.
Based on Pitcairn's 13F filing for Q4 2025.